Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma

Exclusion Criteria

• •1. Patients with cervical lymph node cN3.
• •2. Have a history of other cancers in the past five years, radical or untreated prostate cancer (Gleason score ≤ 6), or complete treatment of breast ductal carcinoma in situ, except for patients with cured skin basal cell carcinoma or squamous cell skin cancer.
• •3. Patients with target lesions who have received radiation therapy or surgery (except biopsy).
• •4. Patients who have previously used chemotherapy, immunotherapy, or biological targeted therapy for primary tumors
• •5. Patients who have participated in other clinical trials within 4 weeks before the test.
• •6. Any of the following conditions in the first 6 months of random grouping: myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, patients with transient ischemic attack or symptomatic pulmonary embolism.
• •7. Patients with hypertension who cannot control well through single antihypertensive medication (systolic blood pressure \>140 mmHg, diastolic blood pressure \>90 mmHg);
• •8. Patients with grade I or above coronary heart disease, arrhythmia (including men with a QTc interval \>450 ms, women \>470 ms), and cardiac insufficiency.
• •9. Urinary protein was greater than ++ and 24-hour urinary protein quantification \>1.0 g.
• •10. Many factors that affect oral medications (such as inability to swallow, nausea, vomiting, chronic diarrhea, and intestinal obstruction).
• •11. Patients with abnormal coagulation function（INR\>1.5、APTT\>1.5 ULN）and bleeding tendency.
• •12. Patients with a history of psychotropic substance abuse that is active or has a mental disorder.
• •13. Patients who required systemic treatment with corticosteroids (\>10 mg prednisone equivalent daily) or other immunosuppressive agents within 2 weeks prior to the first use of the study drug.
• •14. Patients with a history of severe allergies or allergies; patients with active autoimmune diseases that may worsen when receiving immunostimulants; patients with type 1 diabetes, vitiligo, psoriasis, or hypothyroidism or hyperthyroidism who do not require immunosuppressive therapy are eligible to participate in the study.
• •15. Patients who have previously been diagnosed with immunodeficiency or known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related diseases. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (HBV) surface antigen is positive at screening, or patients with positive HCV RNA \[ribonucleic acid\] when positive for anti-HCV antibody screening test.
• •16. Vaccination within 4 weeks prior to randomization, except for inactivated vaccines.
• •17. Pregnant or lactating women who are in the reproductive period but have not taken effective contraceptive measures.
• •18. The investigator believes that it is inappropriate for individuals to participate in the trial: having, for example, severe acute or chronic medical conditions (including immune colitis, inflammatory bowel disease, non-infectious pneumonia, pulmonary fibrosis) or mental illness (including recent time \[within the past year\] or active suicidal ideation or behavior) .
• •19. With a history of tuberculosis or antituberculosis treatment.